Piliers cl\u00e9s de la prise en charge clinique :<\/h3>\n\n- Ajustement de la dose d'entra\u00eenement :<\/strong> R\u00e9duire le volume d'entra\u00eenement ax\u00e9 sur l'endurance chronique de haute intensit\u00e9 (g\u00e9n\u00e9ralement d\u00e9fini comme >10 heures par semaine pendant de nombreuses ann\u00e9es) 1<\/sup>).<\/li>\n
- Stabilit\u00e9 du rythme et risque de r\u00e9cidive :<\/strong> Implement therapeutic exercise protocols, such as Aerobic Interval Training (AIT), which have been shown to actively reduce Afib burden.2<\/sup><\/li>\n
- Stroke Prevention:<\/strong> Adherence to Oral Anticoagulation (OAC) guidelines based on individual risk scores (e.g., CHA2DS2-VASc) is critical and often outweighs athletic goals, as successful ablation does not universally guarantee safety from stroke.4<\/sup><\/li>\n<\/ol>\n
II. Physiopathologie et probabilit\u00e9 statistique de la r\u00e9cidive de la FA<\/h2>\nA. Le m\u00e9canisme causal : entra\u00eenement d'endurance et remodelage auriculaire<\/h3>\n
The risk of Afib in Masters athletes is inextricably linked to the physiological adaptations induced by sustained, high-volume training, often summarized by the J- or U-shaped curve model of exercise dose and cardiovascular risk.5<\/sup><\/p>\nSubstrat structural et \u00e9lectrique cardiaque<\/h4>\n
Chronic volume loading inherent to endurance sports (such as cycling, running, or swimming) results in specific cardiac remodeling, leading to the “athlete’s heart”.7<\/sup> While much attention is paid to ventricular changes, it is the atrial remodeling that predisposes the athlete to Afib. This remodeling includes:<\/p>\n\n- Biatrial Dilation:<\/strong> Hypertrophie des oreillettes gauche et droite.7<\/sup><\/li>\n
- Fibrose myocardique<\/strong> Le d\u00e9veloppement de cicatrices microscopiques (fibrose) dans les parois auriculaires.8<\/sup><\/li>\n<\/ul>\n
Cette fibrose est particuli\u00e8rement dangereuse car elle cr\u00e9e un environnement tissulaire \u00e9lectriquement h\u00e9t\u00e9rog\u00e8ne, constituant un substrat tr\u00e8s propice \u00e0 la formation de circuits \u00e9lectriques de macro-r\u00e9entr\u00e9e. Ces circuits soutiennent l'activit\u00e9 \u00e9lectrique d\u00e9sorganis\u00e9e caract\u00e9ristique de la Fibrillation Atriale.8<\/sup><\/p>\nD\u00e9s\u00e9quilibres autonomes comme d\u00e9clencheurs<\/h4>\n
In addition to structural changes, endurance athletes experience profound fluctuations in their autonomic nervous system. They typically exhibit exaggerated vagal tone at rest, leading to sinus bradycardia. However, intense or competitive exercise induces a powerful sympathetic surge. This swing in autonomic activity significantly shortens the atrial refractory period, acting as a potent ectopic trigger that can initiate Afib episodes.8<\/sup> In the Masters athlete (50+), the combination of exercise-induced remodeling and age-related risk factors (such as hypertension or obesity, even if well-controlled) compounds this electrophysiological vulnerability.1<\/sup><\/p>\nB. Statistical Data on Recurrence Probability Post-Treatment<\/h3>\n
The probability of remaining free from atrial arrhythmia after treatment is notably challenged by the continuation of the underlying etiological stimulus (intense training).<\/p>\n
Recurrence Post-Catheter Ablation (PVI)<\/h4>\n
For athletes undergoing catheter ablation, specifically Pulmonary Vein Isolation (PVI), the recurrence rates are often problematic. Observational data suggest that endurance athletes tend to experience higher rates of atrial arrhythmia recurrence<\/strong> than sedentary non-athletes after the procedure.10<\/sup> Crucially, this recurrence often manifests not as the original Afib, but as flutter atypique<\/strong>.10<\/sup> This phenomenon suggests that the disease process has progressed, with the original pulmonary vein triggers successfully isolated, but the underlying fibrotic substrate driving new arrhythmias elsewhere in the atrial tissue (non-pulmonary vein dependent).10<\/sup><\/p>\nOne study comparing PVI outcomes reported that athletes experienced similar arrhythmia-free survival at 3 years compared to non-endurance controls (87% vs. 85%, p=0.88).9<\/sup> However, another comparison showed recurrence rates (freedom from AF and antiarrhythmic therapy) were 34% in athletes versus 48% in controls after 3 years.9<\/sup> The implication of this variation is that while PVI may be effective initially for vagally-mediated Afib common in athletes, the long-term maintenance of intense training will relentlessly drive further remodeling and increase the probability of eventual recurrence or progression to more complex arrhythmias like atrial flutter.10<\/sup><\/p>\nQuantitative Benefit of Training Modification<\/h4>\n
A structured reduction and modification of exercise volume are strongly supported by outcome data, translating to a favorable reduction in recurrence probability.<\/p>\n
\n- Relative Risk Reduction:<\/strong> Structured exercise intervention has been associated with an overall reduced risk of AF recurrence<\/strong> compared to control groups, quantified by a Relative Risk (RR) of 82<\/strong> (95% CI: 0.68 to 0.99, p=0.04).3<\/sup> This reduction suggests that thoughtful exercise prescription, focused on health maintenance rather than maximum performance, can be genuinely therapeutic.<\/li>\n
- Reduction in Afib Burden:<\/strong> Specifically, structured Aerobic Interval Training (AIT) was found to reduce the mean time an athlete spent in Afib from 1% to 8.1%<\/strong> compared to a control group, alongside improvements in cardiopulmonary fitness (V02max).2<\/sup><\/li>\n<\/ul>\n
C. The Unacceptable Risk of Stroke<\/h3>\n
The decision to continue intense training must be weighed against the persistent risk of stroke, particularly because the athlete is over 50 years of age. Age 50+ likely results in a CHA2DS2-VASc score of at least 1 (for age), possibly 2 or higher if other risk factors like hypertension or diabetes are present.4<\/sup><\/p>\nStroke prevention guidelines dictate the use of Oral Anticoagulation (OAC) based on the CHA2DS2-VASc score, regardless of the perceived success of Afib treatment.<\/p>\n
\n- OAC Discontinuation Risk:<\/strong> Observational studies indicate that for patients with a CHA2DS2-VASc score > 2, discontinuing OAC >3 months after catheter ablation led to a substantially increased stroke risk, quantified by a Hazard Ratio (HR) of 2.48<\/strong> (95% CI, 1.11\u20135.52; P<0.05).4<\/sup><\/li>\n
- Ablation Limitations:<\/strong> Randomized clinical trials have, to date, not demonstrated reductions in stroke risk<\/strong> after catheter ablation.4<\/sup><\/li>\n<\/ul>\n
This data underscores the fact that ablation treats the arrhythmia symptom, but may not fully resolve the underlying pathology that drives thromboembolic risk. Therefore, the probability of stroke is overwhelmingly dependent on the CHA2DS2-VASc score, not on the ability to return to intense training. If OAC is required, the athlete must be counseled that contact or high-trauma sports are contraindicated due to bleeding risk.11<\/sup><\/p>\nIII. Suggested Course of Action: Detailed Training and Clinical Protocols<\/h2>\n
The course of action for the Masters athlete (50+) with treated Afib should focus on risk mitigation and structured exercise for cardiac resilience.<\/p>\n
A. Phased Training Modification Protocol<\/h3>\n
The transition from a high-volume endurance regimen to a therapeutic regimen requires structured phasing and communication, especially regarding the established link between high-intensity training and Afib burden.5<\/sup><\/p>\n\u00a0<\/sup><\/p>\n\n\n\nPhase<\/strong><\/td>\nDur\u00e9e<\/strong><\/td>\nActivity\/Goal<\/strong><\/td>\nClinical Rationale and Guidance<\/strong><\/td>\n<\/tr>\n\nPhase 1: Immediate Post-Treatment Recovery<\/strong><\/td>\nInitial 4\u20138 Weeks<\/td>\n Complete cessation or very light, non-competitive activity (e.g., walking).<\/td>\n Allows for myocardial healing and stabilization of sinus rhythm following ablation or cardioversion.12<\/sup> Resumption of structured sports activity should begin only one month after ablation<\/strong>, provided the procedure is verified as successful.11<\/sup><\/td>\n<\/tr>\n\nPhase 2: Therapeutic Load & Maintenance<\/strong><\/td>\nOngoing (Long-Term)<\/td>\n Moderate-to-Vigorous Structured Aerobic Exercise, prioritizing shorter, higher-intensity intervals (AIT) over long, continuous duration.<\/td>\n The primary long-term objective is to maintain cardiorespiratory fitness (improved V02max) and cardiac function (improved Left Ventricular Ejection Fraction, LVEF 3<\/sup>), while avoiding the chronic volume strain that induced the Afib.13<\/sup> The suggested target is approximately 210 minutes per week<\/strong> of moderate-to-vigorous aerobic exercise.4<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nThe importance of using Entra\u00eenement par intervalles a\u00e9robie<\/strong> in Phase 2 cannot be overstated, as subgroup analysis suggests interval training offers greater benefit in reducing AF recurrence<\/strong> compared to continuous training.3<\/sup> A generalized return to long, slow distance training (>10 hours\/week) should be actively discouraged, as this risks re-inducing the remodeling that caused the original arrhythmia.1<\/sup><\/p>\nB. Clinical Management Considerations<\/h3>\n\n- Antiarrhythmic Medication and Performance:<\/strong> Athletes are often intolerant of or unwilling to take medications like Beta-blockers, as these drugs profoundly reduce peak exercise capacity, measured by V02max.14<\/sup> Catheter ablation is frequently preferred because it offers the possibility of eradicating Afib and allowing a return to competition without daily performance-limiting drug therapy.14<\/sup> If “pill-in-the-pocket” Class I drugs (flecainide or propafenone) are used for acute cardioversion, the athlete must refrain from intensive sports until two half-lives of the drug have elapsed<\/strong> (up to 2 days) due to the risk of pro-arrhythmic effects during adrenergic stress.11<\/sup><\/li>\n
- Monitoring and Evaluation:<\/strong> All athletes must be managed in a specialized sports cardiology center.1<\/sup> Exercise stress testing should be conducted using protocols that mimic the athlete\u2019s sport to ensure the ventricular rate remains controlled during maximal exertion, confirming therapeutic efficacy.1<\/sup><\/li>\n
- Anticoagulation Status:<\/strong> OAC status must be re-evaluated continuously. In high-risk athletes (CHA2DS2-VASc >2), OAC must be continued indefinitely, even if Afib appears suppressed.4<\/sup> This clinical requirement guides participation in sports; sports with high risk of bodily contact or trauma are strictly not recommended for anticoagulated individuals.11<\/sup><\/li>\n<\/ol>\n
IV. Summary and Integration of Lipid Management (Stoicescu et al., 2025)<\/h2>\n
The holistic management of a Masters athlete (50+) requires addressing not only the electrophysiological disorder (Afib) but also the generalized cardiovascular risk, including lipid metabolism. The provided review paper, \u201cHDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications\u201d<\/strong> 15<\/sup>, provides essential context for managing atherosclerotic risk (ASCVD) in this population.<\/p>\nA. Paper Summary: HDL Function Versus Small Dense LDL<\/h3>\n
The review by Stoicescu, Vacarescu, and Cozma highlights a significant paradigm shift in lipidology: the focus has moved away from High-Density Lipoprotein Cholesterol (HDL-C) concentration toward functional capacity and aggressive reduction of atherogenic particles.17<\/sup><\/p>\n\n- HDL Focus: Function over Quantity:<\/strong> While HDL traditionally was considered cardioprotective, pharmacologically increasing HDL-C concentration\u2014via agents like Niacin (AIM-HIGH, HPS2-THRIVE trials) or CETP inhibitors (ILLUMINATE, ACCELERATE trials)\u2014did not consistently reduce cardiovascular events.16<\/sup> The predictive and protective value lies instead in HDL functionality<\/strong>, particularly its Cholesterol Efflux Capacity (CEC)<\/strong>, which represents its ability to remove cholesterol from macrophages in arterial plaques.16<\/sup><\/li>\n
- sdLDL: The Principal Atherogenic Target:<\/strong> Small Dense Low-Density Lipoprotein (sdLDL) particles are identified as critically atherogenic.16<\/sup> Their physical characteristics\u2014small size, higher density, and low antioxidant content\u2014allow them to penetrate the arterial intima efficiently and undergo oxidative modification.15<\/sup> Furthermore, their prolonged plasma half-life (up to 74 hours) increases their exposure time to the endothelial environment.15<\/sup> Elevated sdLDL concentrations are strongly associated with increased ASCVD event risk (Adjusted HRs: 1.21 to 1.52).16<\/sup><\/li>\n
- Therapeutic Consensus:<\/strong> Current guidelines prioritize reducing the overall burden of atherogenic lipoproteins, measured pragmatically by non-HDL-C or Apolipoprotein B (ApoB), which effectively targets sdLDL and remnant particles. Statins and PCSK9 inhibitors remain the foundation of therapy, reducing LDL-C and ApoB.16<\/sup><\/li>\n<\/ol>\n
B. Third-Order Integration: Dual Risk Management Strategy<\/h3>\n
The physiological mechanisms driving Afib risk (remodeling\/fibrosis) and those driving atherosclerotic risk (sdLDL accumulation\/inflammation) often overlap in the aging athlete. The approach must be comprehensive.<\/p>\n
The necessity of managing Afib recurrence through exercise moderation paradoxically supports optimizing lipid profile via lifestyle:<\/p>\n
\n- Lifestyle Synergy:<\/strong> Structured physical activity (moderate-to-vigorous exercise) and appropriate dietary modifications (e.g., Mediterranean, rich in unsaturated fats like olive oil 16<\/sup>, and low in refined carbohydrates) simultaneously address both cardiac risks. These changes improve overall cardiometabolic profile, enhance HDL functional capacity (increasing CEC and antioxidant potential), and reduce plasma triglyceride levels, thereby diminishing the hepatic production of sdLDL.16<\/sup><\/li>\n
- Targeted Residual Risk Mitigation (Omega-3):<\/strong> Given the high ASCVD risk associated with sdLDL and remnant particles, pharmacological intervention may be warranted if hypertriglyceridemia (e.g., > 150 mg\/dL) persists despite optimal statin therapy and lifestyle changes. High-dose pharmaceutical-grade Eicosapentaenoic Acid (EPA) demonstrated a 25% relative risk reduction in major cardiovascular events in the REDUCE-IT trial.16<\/sup> This is a targeted therapy for the residual risk driven by sdLDL.<\/li>\n
- Critical Nuance in EPA Use:<\/strong> A vital consideration for a patient with established Afib is the recognized possibility of increased Afib incidence associated with high-dose omega-3 fatty acids.16<\/sup> The decision to use high-dose EPA requires careful consultation with the electrophysiologist to balance the certain benefit of ASCVD risk reduction against the potential for exacerbating the underlying arrhythmia.<\/li>\n<\/ol>\n
V. Conclusions and Recommendations<\/h2>\n
For the Masters athlete (age 50+) successfully treated for Atrial Fibrillation, the clinical data strongly indicate that continued intense training represents an elevated, medically unacceptable risk to long-term cardiac stability. The need to slow and restructure intense training is a mandatory component of therapy, not a subjective lifestyle choice.<\/p>\n
The statistical probabilities overwhelmingly support intervention:<\/p>\n
\n- The probability of Afib recurrence and progression (e.g., to atypical flutter) remains high<\/strong> if the athlete maintains chronic, high-volume endurance training, as this perpetuates the underlying atrial fibrosis.8<\/sup><\/li>\n
- Implementing a structured, therapeutic exercise dose (approximately 210 minutes per week of moderate-to-vigorous activity, favoring intervals) actively reduces the probability of AF recurrence (RR 82).3<\/sup><\/li>\n
- The probability of a stroke event increases substantially (HR > 2.5<\/strong>) if a high-risk athlete (CHA2DS2-VASc >2) prematurely discontinues OAC, underscoring that rhythm stability does not negate thromboembolic risk.4<\/sup><\/li>\n<\/ul>\n
Recommended Course of Action<\/h3>\n\n- Mandatory Training Shift:<\/strong> The athlete must transition their training goal from maximal endurance performance to cardiovascular health maintenance. This involves reducing volume below chronic high-dose thresholds (i.e., less than 10 hours per week of high-intensity activity) and emphasizing structured interval training for sustained fitness and reduced Afib burden.<\/li>\n
- Stroke Prevention Adherence:<\/strong> OAC status must adhere strictly to guideline recommendations based on the CHA2DS2-VASc score. For most Masters athletes over 50 with treated Afib, continued OAC is required, necessitating the avoidance of contact or high-trauma sports.<\/li>\n
- Holistic Risk Management:<\/strong> Integrate the management of Afib with the control of atherosclerotic risk (ASCVD). Prioritize lifestyle factors (dietary fat composition, carbohydrate restriction) that enhance HDL function and reduce the highly atherogenic sdLDL particles.16<\/sup> Any adjunctive therapy, such as high-dose EPA for hypertriglyceridemia, requires careful consideration due to the potential interaction with Afib burden.<\/li>\n
- Expert Monitoring:<\/strong> The athlete\u2019s return to play and training intensity must be guided by a cardiology team specializing in sports electrophysiology, using serial monitoring and exercise stress testing to confirm rhythm and rate control during exertion.1<\/sup><\/li>\n<\/ol>\n
![\"\"](\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/04\/afib-the-endurance-paradox-800px1.jpg\")
![\"\"](\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/04\/afib-the-endurance-paradox-800px2.jpg\")
![\"\"](\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/04\/afib-the-endurance-paradox-800px3.jpg\")
<\/h3>\nR\u00e9f\u00e9rences<\/h3>\n\n- Mont L, Elosua R, Brugada J. Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter.\u00a0Europace<\/i>. 2009;11(1):11-17. doi:10.1093\/europace\/eun289<\/li>\n
- Malmo V, Nes BM, Amundsen BH, et al. Aerobic Interval Training Reduces the Burden of Atrial Fibrillation in the Short Term: A Randomized Trial.\u00a0Trafic<\/i>. 2016;133(5):466-473. doi:10.1161\/CIRCULATIONAHA.115.018220<\/li>\n
- Fukata E, Hardani R, Mukti N, Pranawa F, Rusnanta F, Rizal A. Physical Exercise Intervention Improves Cardiac Function and Reduce Recurrences in Non-permanent Atrial Fibrillation: A Systematic Review and Meta-analysis.\u00a0J Saudi Heart Assoc<\/i>. 2025;37(4):1459. Published 2025 Oct 10. doi:10.37616\/2212-5043.1459<\/li>\n
- Noseworthy PA, Yao X, Deshmukh AJ, et al. Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation.\u00a0J Am Heart Assoc<\/i>. 2015;4(11):e002597. Published 2015 Nov 5. doi:10.1161\/JAHA.115.002597<\/li>\n
- Guasch E, Mont L. Diagnosis, pathophysiology, and management of exercise-induced arrhythmias.\u00a0Nat Rev Cardiol<\/i>. 2017;14(2):88-101. doi:10.1038\/nrcardio.2016.173<\/li>\n
- Pelliccia A, Maron BJ, Di Paolo FM, et al. Prevalence and clinical significance of left atrial remodeling in competitive athletes.\u00a0J Am Coll Cardiol<\/i>. 2005;46(4):690-696. doi:10.1016\/j.jacc.2005.04.052<\/li>\n
- Benito B, Gay-Jordi G, Serrano-Mollar A, et al. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training.\u00a0Trafic<\/i>. 2011;123(1):13-22. doi:10.1161\/CIRCULATIONAHA.110.938282<\/li>\n
- Katritsis G, Calkins H. Catheter Ablation of Atrial Fibrillation – Techniques and Technology.\u00a0Arrhythm Electrophysiol Rev<\/i>. 2012;1(1):29-33. doi:10.15420\/aer.2012.1.29<\/li>\n
- Calvo N, Mont L, Tamborero D, et al. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes.\u00a0Europace<\/i>. 2010;12(1):30-36. doi:10.1093\/europace\/eup320<\/li>\n
- Heidb\u00fcchel H, Panhuyzen-Goedkoop N, Corrado D, et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers.\u00a0Eur J Cardiovasc Prev Rehabil<\/i>. 2006;13(4):475-484. doi:10.1097\/01.hjr.0000216543.54066.72<\/li>\n
- Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.\u00a0Eur Heart J<\/i>. 2021;42(1):17-96. doi:10.1093\/eurheartj\/ehaa605<\/li>\n
- Elliott AD, Mahajan R, Lau DH, Sanders P. Atrial Fibrillation in Endurance Athletes: From Mechanism to Management.\u00a0Cardiol Clin<\/i>. 2016;34(4):567-578. doi:10.1016\/j.ccl.2016.06.006<\/li>\n
- Menezes AR, Lavie CJ, De Schutter A, et al. Lifestyle modification in the prevention and treatment of atrial fibrillation.\u00a0Prog Cardiovasc Dis<\/i>. 2015;58(2):117-125. doi:10.1016\/j.pcad.2015.07.001<\/li>\n
- Lobo HM, Naves \u00cdG, Mar\u00e7al SB, Canzi CC, Rodrigues ABS, Menezes AS Jr. Atrial Fibrillation in Endurance Training Athletes: Scoping Review.\u00a0Rev Cardiovasc Med<\/i>. 2023;24(6):155. Published 2023 May 26. doi:10.31083\/j.rcm2406155<\/li>\n
- Stoicescu C, Vacarescu C, Cozma D. HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications.\u00a0J Clin Med<\/i>. 2025;14(14):4945. Published 2025 Jul 12. doi:10.3390\/jcm14144945<\/li>\n
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.\u00a0N Engl J Med<\/i>. 2019;380(1):11-22. doi:10.1056\/NEJMoa1812792<\/li>\n
- \u00a0<\/span>Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events.\u00a0N Engl J Med<\/i>. 2014;371(25):2383-2393. doi:10.1056\/NEJMoa1409065<\/li>\n<\/ol>","protected":false},"excerpt":{"rendered":"
D\u00e9couvrez \u201c l'athl\u00e8te v\u00e9t\u00e9ran \u201d. C'est une personne de plus de 50 ans qui a l'impression d'\u00eatre dans la force de l'\u00e2ge. Elle court de longues courses, fait du v\u00e9lo sur des centaines de kilom\u00e8tres et passe des heures dans la piscine. Pour le monde ext\u00e9rieur, elle incarne l'image de la sant\u00e9. Elle a un pouls au repos lent et r\u00e9gulier, et beaucoup d'\u00e9nergie.<\/p>","protected":false},"author":16,"featured_media":8302,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[228,218,225,226],"tags":[],"class_list":["post-8301","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-athletes-and-heart-risk","category-exercise-athletes-and-aging","category-risk-genetics-special-populations","category-special-populations"],"acf":[],"yoast_head":"\n
Cardiovascular Risk Management and Training Modification for the Masters Athlete (50+) with Treated Atrial Fibrillation: An Expert Report - The Premiere Heart Health Education Platform<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curingheartdisease.com\/fr\/gestion-du-risque-cardiovasculaire-et-modification-de-lentrainement-pour-lathlete-veteran-de-50-ans-atteint-de-fibrillation-auriculaire-traitee-un-rapport-dexpert\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiovascular Risk Management and Training Modification for the Masters Athlete (50+) with Treated Atrial Fibrillation: An Expert Report - The Premiere Heart Health Education Platform\" \/>\n<meta property=\"og:description\" content=\"Meet the "Masters Athlete." This is a person over age 50 who feels like they are in the prime of their life. They run long races, bike for hundreds of miles, and spend hours in the pool. To the outside world, they look like the picture of health. They have a slow, steady resting pulse and plenty of energy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curingheartdisease.com\/fr\/gestion-du-risque-cardiovasculaire-et-modification-de-lentrainement-pour-lathlete-veteran-de-50-ans-atteint-de-fibrillation-auriculaire-traitee-un-rapport-dexpert\/\" \/>\n<meta property=\"og:site_name\" content=\"The Premiere Heart Health Education Platform\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/curingheartdisease\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T14:08:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-02T16:40:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-06.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peter Megdal PhD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:site\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peter Megdal PhD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/\"},\"author\":{\"name\":\"Peter Megdal PhD\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\"},\"headline\":\"Cardiovascular Risk Management and Training Modification for the Masters Athlete (50+) with Treated Atrial Fibrillation: An Expert Report\",\"datePublished\":\"2025-03-28T14:08:44+00:00\",\"dateModified\":\"2026-08-02T16:40:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/\"},\"wordCount\":2738,\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/post-image-06.jpg\",\"articleSection\":[\"Athletes and Heart Risk\",\"Exercise, Athletes and Aging\",\"Risk, Genetics and Special Populations\",\"Special Populations\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/\",\"name\":\"Cardiovascular Risk Management and Training Modification for the Masters Athlete (50+) with Treated Atrial Fibrillation: An Expert Report - The Premiere Heart Health Education Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/post-image-06.jpg\",\"datePublished\":\"2025-03-28T14:08:44+00:00\",\"dateModified\":\"2026-08-02T16:40:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/post-image-06.jpg\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/post-image-06.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiovascular Risk Management and Training Modification for the Masters Athlete (50+) with Treated Atrial Fibrillation: An Expert Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"name\":\"The Premiere Heart Health Education Platform\",\"description\":\"To make available to the public the state of the art information on how to reverse heart disease. This is an evidence-based organization utilizing the best available science, including diet, exercise drugs, and other resources to best fight this disease.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curingheartdisease.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\",\"name\":\"Curing Heart Disease, LLC\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"width\":512,\"height\":512,\"caption\":\"Curing Heart Disease, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/curingheartdisease\",\"https:\\\/\\\/x.com\\\/RMHDInc\",\"https:\\\/\\\/www.instagram.com\\\/rmhdinc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm8dh9c_D5RfJL7Z1f-yY4w\"],\"description\":\"Curing Heart Disease, LLC is an independent cardiovascular health education organization that publishes evidence-based articles, videos, podcasts, and educational tools about cardiovascular disease prevention, lipid science, nutrition, exercise, and related health topics.\",\"founder\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"foundingPerson\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"knowsAbout\":[\"Cardiovascular health\",\"Cardiovascular disease prevention\",\"Heart disease education\",\"Nutrition\",\"Exercise\",\"Lipid science\",\"Atherosclerosis\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\",\"givenName\":\"Peter\",\"familyName\":\"Megdal\",\"honorificSuffix\":\"PhD\",\"jobTitle\":\"Nutrition Researcher and Cardiovascular Health Educator\",\"description\":\"Peter Megdal, PhD, is a nutrition researcher, cardiovascular health educator, published researcher, and longtime competitive cyclist. He earned a PhD in nutrition from the University of Massachusetts and publishes evidence-based cardiovascular health education through Curing Heart Disease.\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\"},\"worksFor\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"affiliation\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"alumniOf\":{\"@type\":\"CollegeOrUniversity\",\"name\":\"University of Massachusetts\"},\"knowsAbout\":[\"Nutrition\",\"Cardiovascular health education\",\"Cardiovascular disease prevention\",\"Lipid science\",\"Exercise physiology\",\"Scientific research\"],\"sameAs\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/author\\\/peter-megdal\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/peter-megdal-56075a2\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gestion du risque cardiovasculaire et modification de l'entra\u00eenement pour l'athl\u00e8te v\u00e9t\u00e9ran (50 ans et plus) atteint de fibrillation auriculaire trait\u00e9e : un rapport d'experts - La premi\u00e8re plateforme d'\u00e9ducation \u00e0 la sant\u00e9 cardiaque","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curingheartdisease.com\/fr\/gestion-du-risque-cardiovasculaire-et-modification-de-lentrainement-pour-lathlete-veteran-de-50-ans-atteint-de-fibrillation-auriculaire-traitee-un-rapport-dexpert\/","og_locale":"fr_FR","og_type":"article","og_title":"Cardiovascular Risk Management and Training Modification for the Masters Athlete (50+) with Treated Atrial Fibrillation: An Expert Report - The Premiere Heart Health Education Platform","og_description":"Meet the \"Masters Athlete.\" This is a person over age 50 who feels like they are in the prime of their life. They run long races, bike for hundreds of miles, and spend hours in the pool. To the outside world, they look like the picture of health. They have a slow, steady resting pulse and plenty of energy.","og_url":"https:\/\/www.curingheartdisease.com\/fr\/gestion-du-risque-cardiovasculaire-et-modification-de-lentrainement-pour-lathlete-veteran-de-50-ans-atteint-de-fibrillation-auriculaire-traitee-un-rapport-dexpert\/","og_site_name":"The Premiere Heart Health Education Platform","article_publisher":"https:\/\/www.facebook.com\/curingheartdisease","article_published_time":"2025-03-28T14:08:44+00:00","article_modified_time":"2026-08-02T16:40:58+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-06.jpg","type":"image\/jpeg"}],"author":"Peter Megdal PhD","twitter_card":"summary_large_image","twitter_creator":"@RMHDInc","twitter_site":"@RMHDInc","twitter_misc":{"\u00c9crit par":"Peter Megdal PhD","Dur\u00e9e de lecture estim\u00e9e":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/#article","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/"},"author":{"name":"Peter Megdal PhD","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53"},"headline":"Cardiovascular Risk Management and Training Modification for the Masters Athlete (50+) with Treated Atrial Fibrillation: An Expert Report","datePublished":"2025-03-28T14:08:44+00:00","dateModified":"2026-08-02T16:40:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/"},"wordCount":2738,"publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-06.jpg","articleSection":["Athletes and Heart Risk","Exercise, Athletes and Aging","Risk, Genetics and Special Populations","Special Populations"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/","url":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/","name":"Gestion du risque cardiovasculaire et modification de l'entra\u00eenement pour l'athl\u00e8te v\u00e9t\u00e9ran (50 ans et plus) atteint de fibrillation auriculaire trait\u00e9e : un rapport d'experts - La premi\u00e8re plateforme d'\u00e9ducation \u00e0 la sant\u00e9 cardiaque","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/#primaryimage"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-06.jpg","datePublished":"2025-03-28T14:08:44+00:00","dateModified":"2026-08-02T16:40:58+00:00","breadcrumb":{"@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/#primaryimage","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-06.jpg","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-06.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.curingheartdisease.com\/cardiovascular-risk-management-and-training-modification-for-the-masters-athlete-50-with-treated-atrial-fibrillation-an-expert-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curingheartdisease.com\/"},{"@type":"ListItem","position":2,"name":"Cardiovascular Risk Management and Training Modification for the Masters Athlete (50+) with Treated Atrial Fibrillation: An Expert Report"}]},{"@type":"WebSite","@id":"https:\/\/www.curingheartdisease.com\/#website","url":"https:\/\/www.curingheartdisease.com\/","name":"La premi\u00e8re plateforme d'\u00e9ducation sur la sant\u00e9 cardiaque","description":"Mettre \u00e0 la disposition du public les informations les plus r\u00e9centes sur la mani\u00e8re d'inverser les maladies cardiaques. Il s'agit d'une organisation fond\u00e9e sur des donn\u00e9es probantes qui utilise la meilleure science disponible, notamment le r\u00e9gime alimentaire, l'exercice physique, les m\u00e9dicaments et d'autres ressources pour lutter au mieux contre cette maladie.","publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curingheartdisease.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.curingheartdisease.com\/#organization","name":"Curing Heart Disease, LLC","url":"https:\/\/www.curingheartdisease.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","width":512,"height":512,"caption":"Curing Heart Disease, LLC"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/curingheartdisease","https:\/\/x.com\/RMHDInc","https:\/\/www.instagram.com\/rmhdinc\/","https:\/\/www.youtube.com\/channel\/UCm8dh9c_D5RfJL7Z1f-yY4w"],"description":"Curing Heart Disease, LLC est une organisation ind\u00e9pendante d'\u00e9ducation \u00e0 la sant\u00e9 cardiovasculaire qui publie des articles, des vid\u00e9os, des podcasts et des outils \u00e9ducatifs fond\u00e9s sur des donn\u00e9es probantes concernant la pr\u00e9vention des maladies cardiovasculaires, la science des lipides, la nutrition, l'exercice physique et des sujets de sant\u00e9 connexes.","founder":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"foundingPerson":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"knowsAbout":["Cardiovascular health","Cardiovascular disease prevention","Heart disease education","Nutrition","Exercise","Lipid science","Atherosclerosis"]},{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD","url":"https:\/\/www.curingheartdisease.com\/peters-story\/","givenName":"Peter","familyName":"Megdal","honorificSuffix":"PhD","jobTitle":"Nutrition Researcher and Cardiovascular Health Educator","description":"Peter Megdal, PhD est chercheur en nutrition, formateur en sant\u00e9 cardiovasculaire, auteur de publications scientifiques et cycliste de comp\u00e9tition de longue date. Titulaire d'un doctorat en nutrition de l'universit\u00e9 du Massachusetts, il diffuse des informations fond\u00e9es sur des donn\u00e9es scientifiques en mati\u00e8re de sant\u00e9 cardiovasculaire via le site \u00ab Curing Heart Disease \u00bb.","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/peters-story\/"},"worksFor":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"affiliation":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"alumniOf":{"@type":"CollegeOrUniversity","name":"University of Massachusetts"},"knowsAbout":["Nutrition","Cardiovascular health education","Cardiovascular disease prevention","Lipid science","Exercise physiology","Scientific research"],"sameAs":["https:\/\/www.curingheartdisease.com\/author\/peter-megdal\/","https:\/\/www.linkedin.com\/in\/peter-megdal-56075a2\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/posts\/8301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/comments?post=8301"}],"version-history":[{"count":20,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/posts\/8301\/revisions"}],"predecessor-version":[{"id":12298,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/posts\/8301\/revisions\/12298"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/media\/8302"}],"wp:attachment":[{"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/media?parent=8301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/categories?post=8301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/tags?post=8301"}],"curies":[{"name":"Bien jou\u00e9","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
II. Physiopathologie et probabilit\u00e9 statistique de la r\u00e9cidive de la FA<\/h2>\nA. Le m\u00e9canisme causal : entra\u00eenement d'endurance et remodelage auriculaire<\/h3>\n
The risk of Afib in Masters athletes is inextricably linked to the physiological adaptations induced by sustained, high-volume training, often summarized by the J- or U-shaped curve model of exercise dose and cardiovascular risk.5<\/sup><\/p>\n Chronic volume loading inherent to endurance sports (such as cycling, running, or swimming) results in specific cardiac remodeling, leading to the “athlete’s heart”.7<\/sup> While much attention is paid to ventricular changes, it is the atrial remodeling that predisposes the athlete to Afib. This remodeling includes:<\/p>\n Cette fibrose est particuli\u00e8rement dangereuse car elle cr\u00e9e un environnement tissulaire \u00e9lectriquement h\u00e9t\u00e9rog\u00e8ne, constituant un substrat tr\u00e8s propice \u00e0 la formation de circuits \u00e9lectriques de macro-r\u00e9entr\u00e9e. Ces circuits soutiennent l'activit\u00e9 \u00e9lectrique d\u00e9sorganis\u00e9e caract\u00e9ristique de la Fibrillation Atriale.8<\/sup><\/p>\n In addition to structural changes, endurance athletes experience profound fluctuations in their autonomic nervous system. They typically exhibit exaggerated vagal tone at rest, leading to sinus bradycardia. However, intense or competitive exercise induces a powerful sympathetic surge. This swing in autonomic activity significantly shortens the atrial refractory period, acting as a potent ectopic trigger that can initiate Afib episodes.8<\/sup> In the Masters athlete (50+), the combination of exercise-induced remodeling and age-related risk factors (such as hypertension or obesity, even if well-controlled) compounds this electrophysiological vulnerability.1<\/sup><\/p>\n The probability of remaining free from atrial arrhythmia after treatment is notably challenged by the continuation of the underlying etiological stimulus (intense training).<\/p>\n For athletes undergoing catheter ablation, specifically Pulmonary Vein Isolation (PVI), the recurrence rates are often problematic. Observational data suggest that endurance athletes tend to experience higher rates of atrial arrhythmia recurrence<\/strong> than sedentary non-athletes after the procedure.10<\/sup> Crucially, this recurrence often manifests not as the original Afib, but as flutter atypique<\/strong>.10<\/sup> This phenomenon suggests that the disease process has progressed, with the original pulmonary vein triggers successfully isolated, but the underlying fibrotic substrate driving new arrhythmias elsewhere in the atrial tissue (non-pulmonary vein dependent).10<\/sup><\/p>\n One study comparing PVI outcomes reported that athletes experienced similar arrhythmia-free survival at 3 years compared to non-endurance controls (87% vs. 85%, p=0.88).9<\/sup> However, another comparison showed recurrence rates (freedom from AF and antiarrhythmic therapy) were 34% in athletes versus 48% in controls after 3 years.9<\/sup> The implication of this variation is that while PVI may be effective initially for vagally-mediated Afib common in athletes, the long-term maintenance of intense training will relentlessly drive further remodeling and increase the probability of eventual recurrence or progression to more complex arrhythmias like atrial flutter.10<\/sup><\/p>\n A structured reduction and modification of exercise volume are strongly supported by outcome data, translating to a favorable reduction in recurrence probability.<\/p>\n The decision to continue intense training must be weighed against the persistent risk of stroke, particularly because the athlete is over 50 years of age. Age 50+ likely results in a CHA2DS2-VASc score of at least 1 (for age), possibly 2 or higher if other risk factors like hypertension or diabetes are present.4<\/sup><\/p>\n Stroke prevention guidelines dictate the use of Oral Anticoagulation (OAC) based on the CHA2DS2-VASc score, regardless of the perceived success of Afib treatment.<\/p>\n This data underscores the fact that ablation treats the arrhythmia symptom, but may not fully resolve the underlying pathology that drives thromboembolic risk. Therefore, the probability of stroke is overwhelmingly dependent on the CHA2DS2-VASc score, not on the ability to return to intense training. If OAC is required, the athlete must be counseled that contact or high-trauma sports are contraindicated due to bleeding risk.11<\/sup><\/p>\n The course of action for the Masters athlete (50+) with treated Afib should focus on risk mitigation and structured exercise for cardiac resilience.<\/p>\n The transition from a high-volume endurance regimen to a therapeutic regimen requires structured phasing and communication, especially regarding the established link between high-intensity training and Afib burden.5<\/sup><\/p>\n \u00a0<\/sup><\/p>\n The importance of using Entra\u00eenement par intervalles a\u00e9robie<\/strong> in Phase 2 cannot be overstated, as subgroup analysis suggests interval training offers greater benefit in reducing AF recurrence<\/strong> compared to continuous training.3<\/sup> A generalized return to long, slow distance training (>10 hours\/week) should be actively discouraged, as this risks re-inducing the remodeling that caused the original arrhythmia.1<\/sup><\/p>\n The holistic management of a Masters athlete (50+) requires addressing not only the electrophysiological disorder (Afib) but also the generalized cardiovascular risk, including lipid metabolism. The provided review paper, \u201cHDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications\u201d<\/strong> 15<\/sup>, provides essential context for managing atherosclerotic risk (ASCVD) in this population.<\/p>\n The review by Stoicescu, Vacarescu, and Cozma highlights a significant paradigm shift in lipidology: the focus has moved away from High-Density Lipoprotein Cholesterol (HDL-C) concentration toward functional capacity and aggressive reduction of atherogenic particles.17<\/sup><\/p>\n The physiological mechanisms driving Afib risk (remodeling\/fibrosis) and those driving atherosclerotic risk (sdLDL accumulation\/inflammation) often overlap in the aging athlete. The approach must be comprehensive.<\/p>\n The necessity of managing Afib recurrence through exercise moderation paradoxically supports optimizing lipid profile via lifestyle:<\/p>\n For the Masters athlete (age 50+) successfully treated for Atrial Fibrillation, the clinical data strongly indicate that continued intense training represents an elevated, medically unacceptable risk to long-term cardiac stability. The need to slow and restructure intense training is a mandatory component of therapy, not a subjective lifestyle choice.<\/p>\n The statistical probabilities overwhelmingly support intervention:<\/p>\n D\u00e9couvrez \u201c l'athl\u00e8te v\u00e9t\u00e9ran \u201d. C'est une personne de plus de 50 ans qui a l'impression d'\u00eatre dans la force de l'\u00e2ge. Elle court de longues courses, fait du v\u00e9lo sur des centaines de kilom\u00e8tres et passe des heures dans la piscine. Pour le monde ext\u00e9rieur, elle incarne l'image de la sant\u00e9. Elle a un pouls au repos lent et r\u00e9gulier, et beaucoup d'\u00e9nergie.<\/p>","protected":false},"author":16,"featured_media":8302,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[228,218,225,226],"tags":[],"class_list":["post-8301","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-athletes-and-heart-risk","category-exercise-athletes-and-aging","category-risk-genetics-special-populations","category-special-populations"],"acf":[],"yoast_head":"\nSubstrat structural et \u00e9lectrique cardiaque<\/h4>\n
\n
D\u00e9s\u00e9quilibres autonomes comme d\u00e9clencheurs<\/h4>\n
B. Statistical Data on Recurrence Probability Post-Treatment<\/h3>\n
Recurrence Post-Catheter Ablation (PVI)<\/h4>\n
Quantitative Benefit of Training Modification<\/h4>\n
\n
C. The Unacceptable Risk of Stroke<\/h3>\n
\n
III. Suggested Course of Action: Detailed Training and Clinical Protocols<\/h2>\n
A. Phased Training Modification Protocol<\/h3>\n
\n\n
\n Phase<\/strong><\/td>\n Dur\u00e9e<\/strong><\/td>\n Activity\/Goal<\/strong><\/td>\n Clinical Rationale and Guidance<\/strong><\/td>\n<\/tr>\n \n Phase 1: Immediate Post-Treatment Recovery<\/strong><\/td>\n Initial 4\u20138 Weeks<\/td>\n Complete cessation or very light, non-competitive activity (e.g., walking).<\/td>\n Allows for myocardial healing and stabilization of sinus rhythm following ablation or cardioversion.12<\/sup> Resumption of structured sports activity should begin only one month after ablation<\/strong>, provided the procedure is verified as successful.11<\/sup><\/td>\n<\/tr>\n \n Phase 2: Therapeutic Load & Maintenance<\/strong><\/td>\n Ongoing (Long-Term)<\/td>\n Moderate-to-Vigorous Structured Aerobic Exercise, prioritizing shorter, higher-intensity intervals (AIT) over long, continuous duration.<\/td>\n The primary long-term objective is to maintain cardiorespiratory fitness (improved V02max) and cardiac function (improved Left Ventricular Ejection Fraction, LVEF 3<\/sup>), while avoiding the chronic volume strain that induced the Afib.13<\/sup> The suggested target is approximately 210 minutes per week<\/strong> of moderate-to-vigorous aerobic exercise.4<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n B. Clinical Management Considerations<\/h3>\n
\n
IV. Summary and Integration of Lipid Management (Stoicescu et al., 2025)<\/h2>\n
A. Paper Summary: HDL Function Versus Small Dense LDL<\/h3>\n
\n
B. Third-Order Integration: Dual Risk Management Strategy<\/h3>\n
\n
V. Conclusions and Recommendations<\/h2>\n
\n
Recommended Course of Action<\/h3>\n
\n
<\/h3>\nR\u00e9f\u00e9rences<\/h3>\n
\n